Long Thesis on BioNTech SE Post-EarningsBioNTech SE presents a compelling long opportunity following its latest earnings report. The company continues to expand beyond COVID-19 vaccines, with a strong pipeline in personalized mRNA cancer therapies, infectious disease vaccines (HIV, tuberculosis, malaria), and autoimmunity treatments. With
